Key facts
- Nanovery’s last known valuation is $7.3M (Apr 2025).
- It has raised $6.3M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Plug and Play Tech Center, Innovate UK, Entrepreneurs First, SFC Capital, BioTools Innovator — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Nanovery
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanovery are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanovery
Developer of an artificial intelligence nanorobot designed for quick and ultra-sensitive detection of challenging biomarkers. The company's platform captures circulating tumor DNA and emits a fluorescent signal, allowing point-of-care detection and predicting the deoxyribonucleic acid evolution of the cancer cells, enabling healthcare professionals to detect cancer and increase the patient's chance of survival significantly.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2018
- Employees
- 17
- Website
- nanovery.co.uk/
- Ownership
- Privately Held (backing)
Nanovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanovery in its N-PORT filings yet. We sweep new filings monthly.